HighTide Therapeutics (2511) Announces Appointment of Chief Medical Officer to Advance CKM Portfolio

Bulletin Express

Feb 02

HighTide Therapeutics, Inc. (2511) has appointed Dr. Filip Surmont as Chief Medical Officer to drive the global strategy, clinical development, and medical affairs of its cardiovascular-kidney-metabolic (CKM) diseases portfolio. The appointment is intended to accelerate clinical programs and heighten the value of the company’s core pipeline.

Dr. Surmont brings over 30 years of experience in healthcare and pharmaceuticals, including 18 years in senior roles at major multinational companies and 16 years in clinical practice. He has played significant roles in the advancement of blockbuster medications and large-scale clinical transformations, including efforts in cardiovascular, metabolic, and renal treatments. He has also authored numerous peer-reviewed articles in high-impact medical journals.

According to the announcement, Dr. Surmont’s appointment reflects HighTide Therapeutics’ continued commitment to building a strong leadership team to further develop and expand its CKM disease-focused programs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1171669641"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1171669641\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1171669641?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-02 16:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171669641","market":"us","top_or_hot":-1,"title":"HighTide Therapeutics (2511) Announces Appointment of Chief Medical Officer to Advance CKM Portfolio","media":"Bulletin Express","content":"<p>HighTide Therapeutics, Inc. (2511) has appointed Dr. Filip Surmont as Chief Medical Officer to drive the global strategy, clinical development, and medical affairs of its cardiovascular-kidney-metabolic (CKM) diseases portfolio. The appointment is intended to accelerate clinical programs and heighten the value of the company’s core pipeline.</p>\n<p>Dr. Surmont brings over 30 years of experience in healthcare and pharmaceuticals, including 18 years in senior roles at major multinational companies and 16 years in clinical practice. He has played significant roles in the advancement of blockbuster medications and large-scale clinical transformations, including efforts in cardiovascular, metabolic, and renal treatments. He has also authored numerous peer-reviewed articles in high-impact medical journals.</p>\n<p>According to the announcement, Dr. Surmont’s appointment reflects HighTide Therapeutics’ continued commitment to building a strong leadership team to further develop and expand its CKM disease-focused programs.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HighTide Therapeutics (2511) Announces Appointment of Chief Medical Officer to Advance CKM Portfolio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHighTide Therapeutics (2511) Announces Appointment of Chief Medical Officer to Advance CKM Portfolio\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-02 16:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HighTide Therapeutics, Inc. (2511) has appointed Dr. Filip Surmont as Chief Medical Officer to drive the global strategy, clinical development, and medical affairs of its cardiovascular-kidney-metabolic (CKM) diseases portfolio. The appointment is intended to accelerate clinical programs and heighten the value of the company’s core pipeline.</p>\n<p>Dr. Surmont brings over 30 years of experience in healthcare and pharmaceuticals, including 18 years in senior roles at major multinational companies and 16 years in clinical practice. He has played significant roles in the advancement of blockbuster medications and large-scale clinical transformations, including efforts in cardiovascular, metabolic, and renal treatments. He has also authored numerous peer-reviewed articles in high-impact medical journals.</p>\n<p>According to the announcement, Dr. Surmont’s appointment reflects HighTide Therapeutics’ continued commitment to building a strong leadership team to further develop and expand its CKM disease-focused programs.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02511","symbol_name":"君圣泰医药-B","start_time":0,"source_url":"","article_id":"1171669641","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171669641","pubTimestamp":1770022234,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"HighTide Therapeutics, Inc. (2511) has appointed Dr. Filip Surmont as Chief Medical Officer to drive the global strategy, clinical development, and medical affairs of its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02511":"君圣泰医药-B"},"translate_title":"HighTide Therapeutics(2511)宣布任命首席医疗官以推进CKM产品组合","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02511":1},"content_text":"HighTide Therapeutics, Inc. (2511) has appointed Dr. Filip Surmont as Chief Medical Officer to drive the global strategy, clinical development, and medical affairs of its cardiovascular-kidney-metabolic (CKM) diseases portfolio. The appointment is intended to accelerate clinical programs and heighten the value of the company’s core pipeline.\nDr. Surmont brings over 30 years of experience in healthcare and pharmaceuticals, including 18 years in senior roles at major multinational companies and 16 years in clinical practice. He has played significant roles in the advancement of blockbuster medications and large-scale clinical transformations, including efforts in cardiovascular, metabolic, and renal treatments. He has also authored numerous peer-reviewed articles in high-impact medical journals.\nAccording to the announcement, Dr. Surmont’s appointment reflects HighTide Therapeutics’ continued commitment to building a strong leadership team to further develop and expand its CKM disease-focused programs.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}